Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Invigor Medical vs NovoCare Pharmacy

Two GLP-1 desks, one scoreboard. We put Invigor Medical and NovoCare Pharmacy head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 9 · Grade B+

Invigor Medical

Visit Invigor Medical Full brief →
vs
No. 78 · Grade C

NovoCare Pharmacy

Visit NovoCare Pharmacy Full brief →

The verdict

Invigor Medical takes this head-to-head.

Invigor Medical scores 88 to 75 on our six-factor Brief Score — An established telehealth pharmacy with a broad metabolic and hormone catalog and a steady price line.

That doesn't make NovoCare Pharmacy a bad call — it's best for readers who want branded wegovy at the lowest manufacturer-direct self-pay price. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
87
58
Supply Reliability
88
78
Transparency
84
68
Access Breadth
82
92
Clinical Oversight
88
72
Track Record
90
94
Invigor MedicalBrief Score 88 · 75NovoCare Pharmacy

Price, coverage & the tracker

Invigor MedicalNovoCare Pharmacy
Brief Score88/100 (B+)75/100 (C)
Semaglutide$199/moFrom $149/mo (brand Wegovy, compounded oral)
Tirzepatide$339/moNot disclosed
CoverageNot disclosedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
On the trackerStableprice stableNewnew to the tracker, no prior reading

Invigor Medical: Long-running operator; mid-market pricing unchanged this cycle.

NovoCare Pharmacy: New to the tracker on 1 August 2026. The published line reads From $149/mo (brand Wegovy, compounded oral) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.